Podcast: Navigating Challenges – The Changing Role Of Big Pharma

Podcast Interview With AstraZeneca's Stefan Woxström

 
• By Lucie Ellis-Taitt
  
Generate a summary of this article
Listen to this article
Beta

Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.

"I have to go beyond just focusing on bringing medicine to patients but also start looking at what health care systems really need."

In this latest instalment of the In Vivo podcast, Stefan Woxström, senior VP of AstraZeneca, Europe and Canada, draws attention to the role big pharma can adopt in delivering preventative and sustainable health care. Woxström analyzes the changing role of technology in disease prevention and looks forward to the future of AstraZeneca. 

Timestamps:

Introduction - 00:00

What concerns do you hold for the future of health care? - 4:50 

How does big pharma need to act to protect innovation? – 7:20 

Role within preventative health- 11:56

Devices in medicine- 16:17

Goals for the business in the next 12-18 months- 22:04

How will work adapt to achieve these aims? - 24:00

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Market Access

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

IV-MarketAccess (Premium-1): Stimulant Medications Don’t Cause Psychosis, New Study Finds

 
• By Nabil

Instead, the new study found children with more severe attention and hyperactivity issues or other mental health conditions such as anxiety were more likely to be medicated for ADHD.

[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By Nabil

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

In Search Of Rare Disease Treatments, Nonprofits Can Lead the Charge

 
• By David Wild

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By Saba Afreen

XXXXtesting